185 related articles for article (PubMed ID: 37537343)
1. Therapeutic targeting of FUBP3 phase separation by GATA2-AS1 inhibits malate-aspartate shuttle and neuroblastoma progression via modulating SUZ12 activity.
Wang X; Guo Y; Chen G; Fang E; Wang J; Li Q; Li D; Hu A; Bao B; Zhou Y; Gao H; Song J; Du X; Zheng L; Tong Q
Oncogene; 2023 Sep; 42(36):2673-2687. PubMed ID: 37537343
[TBL] [Abstract][Full Text] [Related]
2. HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression.
Song H; Li D; Wang X; Fang E; Yang F; Hu A; Wang J; Guo Y; Liu Y; Li H; Chen Y; Huang K; Zheng L; Tong Q
J Hematol Oncol; 2020 Mar; 13(1):24. PubMed ID: 32216806
[TBL] [Abstract][Full Text] [Related]
3. Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF.
Zhao X; Li D; Huang D; Song H; Mei H; Fang E; Wang X; Yang F; Zheng L; Huang K; Tong Q
Mol Ther; 2018 Mar; 26(3):755-773. PubMed ID: 29398485
[TBL] [Abstract][Full Text] [Related]
4. A feedback loop between GATA2-AS1 and GATA2 promotes colorectal cancer cell proliferation, invasion, epithelial-mesenchymal transition and stemness via recruiting DDX3X.
Pan Y; Zhu Y; Zhang J; Jin L; Cao P
J Transl Med; 2022 Jun; 20(1):287. PubMed ID: 35752837
[TBL] [Abstract][Full Text] [Related]
5. A MYC target long non-coding RNA GATA2-AS1 regulates non-small cell lung cancer growth.
Zhang L; Gao L; Shao M; Sun GY
Neoplasma; 2019 Nov; 66(6):954-962. PubMed ID: 31607132
[TBL] [Abstract][Full Text] [Related]
6. Silencing of long non-coding RNA DLX6-AS1 weakens neuroblastoma progression by the miR-513c-5p/PLK4 axis.
Jia P; Wei E; Liu H; Wu T; Wang H
IUBMB Life; 2020 Dec; 72(12):2627-2636. PubMed ID: 33031637
[TBL] [Abstract][Full Text] [Related]
7. HNF4A-AS1-encoded small peptide promotes self-renewal and aggressiveness of neuroblastoma stem cells via eEF1A1-repressed SMAD4 transactivation.
Song H; Wang J; Wang X; Yuan B; Li D; Hu A; Guo Y; Cai S; Jin S; Zhou Y; Li Q; Chen G; Gao H; Zheng L; Tong Q
Oncogene; 2022 Apr; 41(17):2505-2519. PubMed ID: 35318442
[TBL] [Abstract][Full Text] [Related]
8. LncRNA GATA2-AS1 suppresses esophageal squamous cell carcinoma progression via the mir-940/PTPN12 axis.
Niu Y; Guo Y; Li Y; Shen S; Liang J; Guo W; Dong Z
Exp Cell Res; 2022 Jul; 416(2):113130. PubMed ID: 35364057
[TBL] [Abstract][Full Text] [Related]
9. LncRNA ZNF674-AS1 drives cell growth and inhibits cisplatin-induced pyroptosis via up-regulating CA9 in neuroblastoma.
Zhao K; Wang X; Jin Y; Zhu X; Zhou T; Yu Y; Ji X; Chang Y; Luo J; Ni X; Guo Y; Yu D
Cell Death Dis; 2024 Jan; 15(1):5. PubMed ID: 38177154
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of circ-CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression.
Li H; Yang F; Hu A; Wang X; Fang E; Chen Y; Li D; Song H; Wang J; Guo Y; Liu Y; Li H; Huang K; Zheng L; Tong Q
EMBO Mol Med; 2019 Dec; 11(12):e10835. PubMed ID: 31709724
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA ASMTL-AS1 inhibits tumor growth and glycolysis by regulating the miR-93-3p/miR-660/FOXO1 axis in papillary thyroid carcinoma.
Feng Z; Chen R; Huang N; Luo C
Life Sci; 2020 Mar; 244():117298. PubMed ID: 31953163
[TBL] [Abstract][Full Text] [Related]
12. Long Noncoding RNA NHEG1 Drives β-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5.
Zhao X; Li D; Yang F; Lian H; Wang J; Wang X; Fang E; Song H; Hu A; Guo Y; Liu Y; Li H; Chen Y; Huang K; Zheng L; Tong Q
Mol Ther; 2020 Mar; 28(3):946-962. PubMed ID: 31982037
[TBL] [Abstract][Full Text] [Related]
13. LncRNA TRG-AS1 promotes glioblastoma cell proliferation by competitively binding with miR-877-5p to regulate SUZ12 expression.
Xie H; Shi S; Chen Q; Chen Z
Pathol Res Pract; 2019 Aug; 215(8):152476. PubMed ID: 31196742
[TBL] [Abstract][Full Text] [Related]
14. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
[TBL] [Abstract][Full Text] [Related]
15. SIRT3-dependent GOT2 acetylation status affects the malate-aspartate NADH shuttle activity and pancreatic tumor growth.
Yang H; Zhou L; Shi Q; Zhao Y; Lin H; Zhang M; Zhao S; Yang Y; Ling ZQ; Guan KL; Xiong Y; Ye D
EMBO J; 2015 Apr; 34(8):1110-25. PubMed ID: 25755250
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity.
Hu A; Chen G; Bao B; Guo Y; Li D; Wang X; Wang J; Li Q; Zhou Y; Gao H; Song J; Du X; Zheng L; Tong Q
Clin Transl Med; 2023 Apr; 13(4):e1235. PubMed ID: 37186134
[TBL] [Abstract][Full Text] [Related]
17. Acetyl-CoA from inflammation-induced fatty acids oxidation promotes hepatic malate-aspartate shuttle activity and glycolysis.
Wang T; Yao W; Li J; He Q; Shao Y; Huang F
Am J Physiol Endocrinol Metab; 2018 Oct; 315(4):E496-E510. PubMed ID: 29763372
[TBL] [Abstract][Full Text] [Related]
18. lncRNA RBM5-AS1 promotes cell proliferation and invasion by epigenetically silencing miR-132/212 in hepatocellular carcinoma cells.
Mu JY; Tian JX; Chen YJ
Cell Biol Int; 2021 Nov; 45(11):2201-2210. PubMed ID: 34019714
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression.
Fang E; Wang X; Wang J; Hu A; Song H; Yang F; Li D; Xiao W; Chen Y; Guo Y; Liu Y; Li H; Huang K; Zheng L; Tong Q
Theranostics; 2020; 10(4):1555-1571. PubMed ID: 32042322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
